Lilly Asia Ventures and existing backer Alexandria Real Estate Equities helped the cancer immunotherapy developer add $80m to the $76m it closed last year.
US-based genomic drug developer KSQ Therapeutics has raised $80m in a series C round backed by pharmaceutical firm Eli Lilly through its Lilly Asia Ventures unit.
Life sciences real estate investment trust Alexandria Real Estate Equities also invested, as did Baillie Gifford, Cowen Healthcare Investments, Invus, Flagship Pioneering, Polaris Partners and Arch Venture Partners.
KSQ is working on cancer treatments, using a tumour-genome platform to discover potential targeted cancer drugs and a T-cell genome platform to develop immune system-based oncology…
